Jupiter Wellness, Inc.: Jupiter Wellness Announces First Patient Dosing for Double-Blinded Placebo Controlled Trial of JW-300 for the Treatment of First Degree Burns

JUPITER, FL / ACCESSWIRE / October 19, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing a cannabinoid receptor agonist for the treatment of first degree burns, announced

Related Keywords

United States ,Kostenloser Wertpapierhandel ,Brian John ,Jupiter Wellness Inc ,Nasdaq ,Jupiter Wellness ,Private Securities Litigation Reform Act ,Jupiter ,Wellness ,Nnounces ,First ,Patient ,Closing ,Double ,Blinded ,Placebo ,Ontrolled ,Trial ,Treatment ,Degree ,Turns ,